Document Detail


Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor.
MedLine Citation:
PMID:  23014816     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
A number of novel oral anticoagulants that directly target factor Xa or thrombin have been developed in recent years. Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor) have shown considerable promise in large-scale, randomised clinical studies for the management of thromboembolic disorders, and have been approved for clinical use in specific indications. Rivaroxaban is licensed for the prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery, the treatment of deep-vein thrombosis and prevention of recurrent venous thromboembolism, and for stroke prevention in patients with non-valvular atrial fibrillation. Based on the clinical trial data for rivaroxaban, feedback on its use in clinical practice and the authors' experience with the use of rivaroxaban, practical guidance for the use of rivaroxaban in special patient populations and specific clinical situations is provided. Although most recommendations are in line with the European summary of product characteristics for the approved indications, additional and, in several areas, different recommendations are given based on review of the literature and the authors' clinical experience.
Authors:
A G G Turpie; R Kreutz; J Llau; B Norrving; S Haas
Related Documents :
16396216 - The historical roots of popular practices in oral health: pistacia lentiscus in cartage...
17992876 - Visual archives in perspective: enlarging on historical medical photographs.
25088126 - Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
22940616 - Further study of translational research for preventive medicine.
20532076 - Management of difficult airway in penetrating cervical spine injury.
7675746 - Genital ulcer disease. management in the hiv era.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-26
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  108     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Alexander GG Turpie MD, Department of Medicine, McMaster University, Hamilton Health Sciences-General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada, Tel.: +1 416 363 6726, Fax: +1 905 628 9505, E-mail: turpiea@mcmaster.ca.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A new era of anticoagulation treatment: optimizing outcomes for atrial fibrillation.
Next Document:  Synchronous double cancers of primary hepatic adenosquamous carcinoma and hepatocellular carcinoma: ...